- Home
- OMER vs ABSI Comparison
OMER vs ABSI Comparison
Compare OMER & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- ABSI
- Stock Information
- Founded
- OMER 1994
- ABSI 2011
- Country
- OMER United States
- ABSI United States
- Employees
- OMER 202
- ABSI N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- OMER Health Care
- ABSI Health Care
- Exchange
- OMER Nasdaq
- ABSI Nasdaq
- Market Cap
- OMER 274.3M
- ABSI 338.0M
- IPO Year
- OMER 2009
- ABSI 2021
- Fundamental
- Price
- OMER $4.06
- ABSI $2.55
- Analyst Decision
- OMER Strong Buy
- ABSI Strong Buy
- Analyst Count
- OMER 5
- ABSI 5
- Target Price
- OMER $18.00
- ABSI $7.98
- AVG Volume (30 Days)
- OMER 730.2K
- ABSI 3.9M
- Earning Date
- OMER 11-12-2025
- ABSI 11-11-2025
- Dividend Yield
- OMER N/A
- ABSI N/A
- EPS Growth
- OMER N/A
- ABSI N/A
- EPS
- OMER N/A
- ABSI N/A
- Revenue
- OMER N/A
- ABSI $4,138,000.00
- Revenue This Year
- OMER N/A
- ABSI $44.71
- Revenue Next Year
- OMER N/A
- ABSI $374.26
- P/E Ratio
- OMER N/A
- ABSI N/A
- Revenue Growth
- OMER N/A
- ABSI 27.32
- 52 Week Low
- OMER $2.95
- ABSI $2.01
- 52 Week High
- OMER $13.60
- ABSI $6.33
- Technical
- Relative Strength Index (RSI)
- OMER 46.53
- ABSI 47.31
- Support Level
- OMER $4.07
- ABSI $2.53
- Resistance Level
- OMER $4.20
- ABSI $2.74
- Average True Range (ATR)
- OMER 0.17
- ABSI 0.17
- MACD
- OMER -0.04
- ABSI 0.03
- Stochastic Oscillator
- OMER 24.49
- ABSI 40.35
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.